Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.
about
DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic TargetsCachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspectiveAutophagy-Related Deubiquitinating Enzymes Involved in Health and DiseaseProtein degradation pathways in Parkinson's disease: curse or blessingStructural Determinants of Ubiquitin Conjugation in Entamoeba histolyticaCharacterization of the ubiquitylating components of the human malaria parasite's protein degradation pathwayDifferential regulation of proteasome functionality in reproductive vs. somatic tissues of Drosophila during aging or oxidative stress.A Plastid Protein That Evolved from Ubiquitin and Is Required for Apicoplast Protein Import in Toxoplasma gondii.SILAC-based quantitative proteomic analysis of human lung cell response to copper oxide nanoparticles.A ubiquitin-specific protease possesses a decisive role for adenovirus replication and oncogene-mediated transformation.Diggin' on u(biquitin): a novel method for the identification of physiological E3 ubiquitin ligase substrates.Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration.Development of inhibitors in the ubiquitination cascade.Ubiquitin-specific proteases as therapeutic targets for the treatment of breast cancerApplication of quantitative proteomics to the integrated analysis of the ubiquitylated and global proteomes of xenograft tumor tissuesHepatitis E virus replication requires an active ubiquitin-proteasome system.E2 superfamily of ubiquitin-conjugating enzymes: constitutively active or activated through phosphorylation in the catalytic cleft.Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown.Ubiquitin-Specific Proteases as Druggable Targets.Role of the ubiquitin ligase E6AP/UBE3A in controlling levels of the synaptic protein ArcSarcoidosis activates diverse transcriptional programs in bronchoalveolar lavage cells.Cullin 3 as a novel target in diverse pathologiesRegulating the ubiquitin/proteasome pathway via cAMP-signaling: neuroprotective potentialThe emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeuticsRole of the ubiquitin-proteasome system in nervous system function and disease: using C. elegans as a dissecting tool.Novel pharmacological modulators of autophagy and therapeutic prospects.Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases.Deubiquitylating enzymes and DNA damage response pathways.USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy.Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218).DUBs, the regulation of cell identity and disease.Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems.MLN4924 therapy as a novel approach in cancer treatment modalities.Modulation of NF-κB Signaling as a Therapeutic Target in Autoimmunity.Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors.Regulation of pluripotency and differentiation by deubiquitinating enzymes.Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication.Ubiquitin-based probes prepared by total synthesis to profile the activity of deubiquitinating enzymes.Molecular mechanisms of acquired proteasome inhibitor resistance.Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease.
P2860
Q26741797-32A12F81-BC61-4145-B4E8-200B28F399B9Q26749418-8D498D68-9C1E-44E7-A1F6-C8A167BAACC5Q26786631-CD3BEA5E-C7D0-4C0F-AB7A-7E8A5F7ACD84Q27026029-0B29B34E-8EC2-42B1-9E8B-F219B23A2B92Q27675352-9E19E6D0-1306-420D-B575-F6DC5FEC3EA8Q27974780-31910B10-CBC8-4A4A-9C01-6C2DB3BAA6FDQ33730010-463FA6BD-CC0F-456A-AB74-8454542D6AF8Q33843880-0C6607DF-D4D2-420B-AAE8-F5E895192C51Q34627914-FE147EAB-1EBF-4E9C-8E91-69E9C53AFD26Q34649757-F5CEA5E5-FCF0-4382-8031-8B31A69A0383Q34733221-D874C20D-EDF8-488D-A77F-E86AED376CF3Q34933261-7AED8388-AC34-4FFC-9C4B-1974F1F25218Q35044801-E9EBA8A0-F407-4870-9A09-8AB28A02D861Q35258016-ABA4E62A-8C91-4984-8EF6-08517ECCECC2Q35652100-5FC0A6DB-DB3B-4DF7-8109-CBA734FBDE7BQ35943360-837E6EF2-4ECF-45BF-9FB7-562CF975E06DQ36158657-18D1674C-8E16-4DC7-BC66-7AC6A1517D6EQ36258034-36B6C164-4F2B-4C1A-877B-00E20C69E3B7Q36509580-9BE57FB9-432F-4C0D-8968-7ACC6C6DD516Q36895506-B4E035FD-EC52-46F3-BAB7-E35C08A4D362Q37129368-61BA621F-E2C9-4C58-9373-8BA8784F7187Q37133559-3D18E27A-FE1B-49D1-B620-AF1742786E13Q37136291-62B2A15C-8AAD-4080-8EC1-A328409012C4Q37517626-9EED3066-AA16-45CB-A057-B5BF6C07536DQ37989861-4A9AEC99-3067-41BC-AAE6-1AAE7798DE61Q38031895-394A9ECE-468A-40BE-A83D-8EEF5B652A53Q38052131-CC143416-1AC2-4773-A4A8-0B62E750C3E2Q38109871-BC902223-DABD-4DC5-8BD4-69F9F5E069E9Q38128426-0B1EBA91-6C87-417D-BA24-585EDE070C23Q38181181-DC37DB65-6CF8-48D5-AC7A-1C50D069C12AQ38336126-68087C21-F3C2-41C6-84E3-8D451C1D61A5Q38492748-B881F6A3-477E-4B8B-9047-7EFE8BBD105AQ38570362-2A618E5E-93F8-4965-8D5B-0BA8ED0E06AEQ38644746-10A421C1-0846-4DA6-B5C0-7F2FFDD8FF6FQ38787197-2F2DB6E7-030D-42FA-953C-F6155B1745DEQ38855269-817B1357-96C2-44F6-BF97-401D739FC650Q39171781-B7286305-4D39-446D-9D30-130B696791AAQ39271369-F1F99287-C34D-48AC-AAEE-E8164D4872D0Q39278628-F913D3D0-A056-4CD1-9E6D-AF1432DF4DBCQ41323064-1D8039FF-5285-4FB7-A6A2-6DC86184E454
P2860
Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pharmacological targets in the ...... rders and infectious diseases.
@ast
Pharmacological targets in the ...... rders and infectious diseases.
@en
type
label
Pharmacological targets in the ...... rders and infectious diseases.
@ast
Pharmacological targets in the ...... rders and infectious diseases.
@en
prefLabel
Pharmacological targets in the ...... rders and infectious diseases.
@ast
Pharmacological targets in the ...... rders and infectious diseases.
@en
P2860
P921
P1476
Pharmacological targets in the ...... rders and infectious diseases.
@en
P2093
Benjamin Nicholson
Mariola J Edelmann
P2860
P356
10.1017/S1462399411002031
P5008
P577
2011-11-17T00:00:00Z